Pay It Forward - TB Champions from South Africa and India

Author:
MSF South Africa
Publisher:
MSF South Africa
Publication Date:
30 October 2019
Tags:
South Africa, Tuberculosis

Tuberculosis (TB) is the world's leading infectious disease killer with 1.8 million deaths every year, and 10 million new cases. It primarily affects the poor and the most vulnerable. Moreover, multidrug-resistant TB (MDR-TB) affects 600,000 people and kills 240,000 annually.

TB is a neglected disease with a desperately weak research pipeline for diagnostics, medicines and vaccines. India and SA are on the frontline in the fight against TB. This killer disease infect 10 million people every year, amongst them over half a million are resistant to treatment. New treatment exists but they are in the hands of big pharmaceutical companies.

Told through the eyes of Bhakti and Goodman, Pay it Forward is a story of resilience, hope and call to action in ensuring medicines shouldn't be a luxury.


InFocus

Drug Price Drop to Save Millions From Developing Tuberculosis

The cost of the drug, rifapentine, will be cut from U.S.$45 to $15 dollars for a recommended three-month course of treatment in 100 nations - including 48 in Africa - where TB is a ... Read more »

Follow AllAfrica

  • Become a Facebook fan
  • Follow AllAfrica on Twitter
  • Read AllAfrica on Newsstand
  • Read AllAfrica on Linkedin
  • Sign up for free newsletters
  • Subscribe to RSS feeds
Don't Miss

AllAfrica publishes around 600 reports a day from more than 140 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.